Consolidated Statements of Stockholders' Equity - USD ($)	Series A preferred stock Preferred Stock	Series A Warrants Common Stock	Series A Warrants Additional Paid-in Capital	Series B Warrants Common Stock	Series B Warrants Additional Paid-in Capital	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2020	$ 1,909,805					$ 27,132	$ 25,826,295	$ (18,245,396)	$ 7,608,031
Beginning Balance (in shares) at Dec. 31, 2020	1,819					542,648
Increase (decrease) in stockholders' equity
Accrued dividend series A preferred stock	$ 129,992						(129,992)		$ (129,992)
Exercise of common warrants		$ 2,060	$ (2,060)	$ 7,468	$ (7,468)
Exercise of common warrants (in shares)		41,192		149,353					334,036
Issuance of common stock and warrants, net of issuance costs						$ 26,953	15,764,857		$ 15,791,810
Issuance of common stock and warrants, net of issuance costs (in shares)						539,063
Exercise of VARs						$ 6	(6)
Exercise of VARs (in shares)						127
Reclassification of Series A preferred stock	$ (2,039,797)
Reclassification of Series A preferred stock (in shares)	(1,819)
Stock-based compensation							636,093		636,093
Net loss								(10,639,146)	(10,639,146)
Ending Balance at Dec. 31, 2021						$ 63,619	42,087,719	(28,884,542)	13,266,796
Ending Balance (in shares) at Dec. 31, 2021						1,272,383
Beginning Balance at Dec. 31, 2020	$ 1,909,805					$ 27,132	25,826,295	(18,245,396)	$ 7,608,031
Beginning Balance (in shares) at Dec. 31, 2020	1,819					542,648
Increase (decrease) in stockholders' equity
Exercise of common warrants (in shares)									334,036
Ending Balance at Dec. 31, 2022						$ 148,354	53,350,126	(48,263,992)	$ 5,234,488
Ending Balance (in shares) at Dec. 31, 2022						2,969,272
Beginning Balance at Dec. 31, 2021						$ 63,619	42,087,719	(28,884,542)	13,266,796
Beginning Balance (in shares) at Dec. 31, 2021						1,272,383
Increase (decrease) in stockholders' equity
Exercise of common warrants						$ 1,200	142,800		144,000
Exercise of common warrants (in shares)						24,000
Issuance of common stock and warrants, net of issuance costs						$ 79,667	7,910,225		7,989,892
Issuance of common stock and warrants, net of issuance costs (in shares)						1,593,333
Exercise of TardiMed Warrants						$ 3,618	(3,618)
Exercise of TardiMed Warrants (in shares)						72,362
Exercise of VARs						$ 60	(60)
Exercise of VARs (in shares)						1,194
Stock-based compensation						$ 190	1,049,123		1,049,313
Stock-based compensation (in shares)						6,000
Conversion of Redeemable Series A Convertible Preferred Stock							2,163,950		2,163,950
Issuance and cancellation of Series B Mirroring Preferred Stock							(13)		(13)
Net loss								(19,379,450)	(19,379,450)
Ending Balance at Dec. 31, 2022						$ 148,354	$ 53,350,126	$ (48,263,992)	$ 5,234,488
Ending Balance (in shares) at Dec. 31, 2022						2,969,272